A drug candidate to prevent adverse reactions due to COVID-19 infection or vaccines
Taken together, the novel drug candidate BH-103 appears to be effective in repairing SA loss through the use of a unique mechanism of action to modify the virus receptor. Through this mechanism, BH-103 is capable of reducing binding affinity, while simultaneously remaining stable under neutral environmental conditions. These findings suggest that this formulation may be developed into a useful drug to prevent and treat disease caused by COVID-19-related antibodies.
Furthermore, the MOA of BH-103 may have a broad spectrum of efficacy, as it acts on all viruses that share this receptor and is not easily blocked by escape mutations. In addition, BH-103 appears to reduce multiple symptoms traceable to ADAA, including cytokine storm in the acute phase and long-haul symptoms in the later phase of convalescence. Vaccine-related adverse effects and autoimmune manifestations related to COVID-19 are also addressed.
The safety of BH-103 appears to be established in animal models. This compound is also easily scalable on a commercial basis, as it is associated with a simple and rapid manufacturing process.
There’s already 6 assassinations of Covid researchers and investigators.
List of DEAD Anti-virus Microbiologists
Four New Discoveries About Safety and Efficacy of COVID Vaccines
There Were More COVID-19 Vaccine Deaths Last Week in US than COVID-19 Deaths
The newest Israeli data indicate ~complete vaccine failure on every level. Remember: Israel used only the @pfizer mRNA shot and followed Pfizer dosing schedule. This data, from the @IsraelMOH telegram account, show nearly all serious cases and deaths are now among the vaccinated.